Production (Stage)
Atara Biotherapeutics, Inc.
ATRA
$7.49
$0.354.90%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 199.73M | 128.94M | 100.44M | 62.39M | 34.70M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 199.73M | 128.94M | 100.44M | 62.39M | 34.70M |
| Cost of Revenue | 164.17M | 168.74M | 180.37M | 188.34M | 209.78M |
| Gross Profit | 35.56M | -39.80M | -79.93M | -125.96M | -175.07M |
| SG&A Expenses | 38.78M | 38.53M | 39.48M | 41.30M | 45.73M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 202.95M | 207.27M | 219.84M | 229.65M | 255.50M |
| Operating Income | -3.22M | -78.33M | -119.41M | -167.26M | -220.80M |
| Income Before Tax | -15.68M | -85.42M | -133.14M | -181.03M | -233.09M |
| Income Tax Expenses | -36.00K | -12.00K | 18.00K | 16.00K | 17.00K |
| Earnings from Continuing Operations | -15.64 | -85.40 | -133.16 | -181.05 | -233.11 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.64M | -85.40M | -133.16M | -181.05M | -233.11M |
| EBIT | -3.22M | -78.33M | -119.41M | -167.26M | -220.80M |
| EBITDA | 2.24M | -73.28M | -114.25M | -162.13M | -215.79M |
| EPS Basic | -3.69 | -12.87 | -25.66 | -39.12 | -52.94 |
| Normalized Basic EPS | -1.70 | -7.48 | -14.50 | -22.92 | -31.59 |
| EPS Diluted | -3.72 | -12.87 | -25.66 | -39.13 | -52.94 |
| Normalized Diluted EPS | -1.72 | -7.48 | -14.50 | -22.92 | -31.59 |
| Average Basic Shares Outstanding | 35.08M | 29.94M | 23.56M | 20.35M | 18.41M |
| Average Diluted Shares Outstanding | 35.17M | 29.94M | 23.56M | 20.35M | 18.41M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |